Currently, Summit Therapeutics Inc [SMMT] is trading at $13.08, down -3.25%. An important factor to consider is whether the stock is rising or falling in short-term value. The SMMT shares have gain 12.76% over the last week, with a monthly amount glided 24.69%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on August 12, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $16. Previously, Citigroup started tracking the stock with Buy rating on May 07, 2024, and set its price target to $7. On March 26, 2024, Stifel initiated with a Buy rating and assigned a price target of $8 on the stock. Janney downgraded its rating to a Neutral. Janney initiated its recommendation with a Buy. Needham reiterated a Buy rating for this stock on April 12, 2018, and downed its price target to $27. In a note dated February 13, 2018, BTIG Research initiated an Buy rating and provided a target price of $33 on this stock.
This stock has fluctuated between a low of $1.52 and a high of $13.80 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $13.08 at the most recent close of the market. An investor can expect a potential return of 7.03% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
Gross Profit Margin for this corporation currently stands at 6.32% with Operating Profit Margin at 523.84%, Pretax Profit Margin comes in at 688.73%, and Net Profit Margin reading is 688.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -1.55 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.56.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.60 points at the first support level, and at 12.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.91, and for the 2nd resistance point, it is at 14.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Summit Therapeutics Inc [NASDAQ:SMMT] is 2.35. On the other hand, the Quick Ratio is 2.35, and the Cash Ratio is 0.21.
Transactions by insiders
Recent insider trading involved Zanganeh Mahkam, Chief Executive Officer, that happened on Mar 27 ’24 when 54321.0 shares were purchased. Chief Executive Officer, Zanganeh Mahkam completed a deal on Mar 26 ’24 to buy 30000.0 shares. Meanwhile, Chief Executive Officer Zanganeh Mahkam bought 26000.0 shares on Mar 27 ’24.
